CureVac Withdraws Agreement to Settle Patent Dispute with Pfizer/BioNTech

Strategic Insights -

CureVac NV has withdrawn its agreement to settle a patent dispute with Pfizer/BioNTech, involving COVID-19 vaccine technology, with CureVac claiming infringement by Pfizer/BioNTech's Comirnaty vaccine. The withdrawal means the dispute will proceed to trial, potentially leading to a lengthy and costly process. This decision comes after CureVac and an affiliate had agreed to settle and discontinue all pending U.S. patent litigation with BioNTech and Pfizer, and establish a framework to resolve ongoing patent litigation outside the U.S.

Key Takeaways:

  • CureVac has withdrawn its agreement to settle a patent dispute with Pfizer/BioNTech, citing COVID-19 vaccine technology infringement.
  • The dispute involves CureVac's mRNA-based COVID-19 vaccine technology and Pfizer/BioNTech's Comirnaty vaccine.
  • The withdrawal means the dispute will proceed to trial, potentially leading to a lengthy and costly process.
  • CureVac will continue to pursue its claims against Pfizer/BioNTech.
  • The patent dispute involves mRNA-based COVID-19 vaccine technology, a key area of innovation in the industry.
  • The dispute may have significant implications for the development and commercialization of COVID-19 vaccines.
  • CureVac will receive a total payment of $740 million plus a single-digit royalty on future sales of COVID-19 vaccines in the United States, as part of a previous agreement to settle the dispute.

Statistics:

  • CureVac will receive $740 million plus a single-digit royalty on future sales of COVID-19 vaccines in the United States.
  • The dispute involves mRNA-based COVID-19 vaccine technology, a key area of innovation in the industry.
  • CureVac will continue to pursue its claims against Pfizer/BioNTech, with the dispute proceeding to trial.

Sources:

  • "CureVac NV and Attributes of BioNTech and Pfizer, Inc. entry into agreement to determine all pending U.S. patent litigation between the companies related to mRNA-based COVID-19 vaccines."
  • CureVac NV, "CureVac and GSK enter into agreements to settle U.S. patent litigation related to mRNA-based COVID-19 vaccines"

Note: The original text does not include a date for the acquisition of CureVac by BioNTech, so it is not included in the analysis.